Nasdaq

KBC Group: KBC welcomes extension of the KBC Group anchoring agreement made among Cera, KBC Ancora, MRBB and Other Stable Shareholders

Together with MRBB and Other Stable Shareholders, Cera and KBC Ancora have confirmed to extend their anchoring agreement with respect to KBC Group NV for a further term of ten years. In doing so, ...
JD Supra

FDA Approves Three Biosimilars - Ahzantive® (aflibercept-mrbb), Nypozi™ (filgrastim-txid), and Pyzchiva® (ustekinumab-ttwe)

On June 28, 2024, the FDA approved three new biosimilars, Formycon and Klinge Biopharma’s Ahzantive® (aflibercept-mrbb), a biosimilar of Regeneron’s ...
PharmiWeb

FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of ...
Monthly Prescribing Reference

FDA Approves Aflibercept Biosimilar Ahzantive

Comparable efficacy between the biosimilar and reference product was demonstrated in the phase 3 MAGELLAN-AMD study. The Food and Drug Administration (FDA) has approved Ahzantive ® (aflibercept-mrbb), ...